Journal of Korean Biological Nursing Science

Korean society of Biological Nursing Science (한국기초간호학회)
권호 표지
DOI QR코드

DOI QR Code

Current Pharmacogenetic Approach for Oxaliplatin-induced Peripheral Neuropathy among Patients with Colorectal Cancer: A Systematic Review

대장암 환자의 옥살리플라틴(oxaliplatin) 유도 말초신경병증에 대한 약물유전학적 접근: 체계적 문헌고찰

  • 안수정 (연세대학교 대학원) ;
  • 최소영 (연세대학교 대학원) ;
  • 정혜정 (세브란스병원) ;
  • 추상희 (연세대학교 간호대학.김모임간호학연구소)
  • Received : 2018.02.08
  • Accepted : 2018.05.08
  • Published : 2018.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Peripheral neuropathy is common among colorectal cancer (CRC) patients who undergo oxaliplatin-based (OXL) chemotherapy. A pharmacogenetic approach can be used to identify patients at high-risk of developing severe neuropathy. This type of approach can also help clinicians determine the best treatment option and prevent severe neurotoxicity. The purpose of this study is to investigate the evidence of pharmacogenetic markers for OXL-induced peripheral neuropathy (OXIPN) in patients with CRC. Methods: A systematic literature search was conducted using the following databases up to December 2017: Pubmed, EMBASE, and CINAHL. We reviewed the genetic risk factors for OXIPN in observational studies and randomized controlled clinical trials (RCTs). All processes were performed independently by two reviewers. Results: Sixteen studies published in English between 2006 and 2017 were included in this review. A genome-wide association approach was used in one study and various candidate genes were tested, based on their functions (e.g., DNA damage or repair, ion channels, anti-oxidants, and nerve growth etc.). The genes associated with incidence or severity of OXIPN were ABCG2, GSTP1, XRCC1, TAC1, and ERCC1. Conclusion: This study highlighted the need and the importance of conducting pharmacogenetic studies to generate evidence of personalized OXIPN symptoms management. Additional studies are warranted to accelerate the tailored interventions used for OXIPN in patients with CRC (NRF-2014R1A1A3054386).

Keywords

References

  1. Argyriou A. Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics. 2015;3(2):187-197. http://doi.org/10.3390/toxics3020187
  2. Argyriou A, Kyritsis A, Makatsoris T, Kalofonos H. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Management and Research. 2014;6:135-147. http://doi.org/10.2147/CMAR.S44261
  3. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncologica. 2007;46(8):1131-1137. http://doi.org/10.1080/02841860701355055
  4. Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nursing. 2011;34(4):E10-20. http://doi.org/10.1097/NCC.0b013e31820251de
  5. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treatment Reviews. 2008;34(4):368-377. http://doi.org/10.1016/j.ctrv.2008.01.003
  6. Chaudhary R, Singh B, Kumar M, Gakhar SK, Saini AK, Parmar VS, et al. Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. Drug Metabolism Reviews. 2015;47(3):281-290. http://doi.org/10.3109/03602532.2015.1047027
  7. Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, et al. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis. Journal of the Peripheral Nervous System. 2015;20(1):15-23. http://doi.org/10.1111/jns.12110
  8. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. The Lancet Oncology. 2011;12(12):1151-1161. http://doi.org/10.1016/s1470-2045(11)70131-0
  9. Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer. 2013;119(19):3570-3577. http://doi.org/10.1002/cncr.28234
  10. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. The Pharmacogenomics Journal. 2013;13(5):403-409. http://doi.org/10.1038/tpj.2012.31
  11. Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group study. Annals of Oncology. 2014;25(2):398-403. http://doi.org/10.1093/annonc/mdt546
  12. Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemotherapy and Pharmacology. 2011;67(5):1179-1187. http://doi.org/10.1007/s00280-010-1466-y
  13. Sereno M, Gutierrez-Gutierrez G, Rubio JM, Apellaniz-Ruiz M, Sanchez-Barroso L, Casado E, et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer. 2017;17(1):63. http://doi.org/10.1186/s12885-016-3031-5
  14. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clincal Cancer Research. 2006;12(10):3050-3056. http://doi.org/10.1158/1078-0432.ccr-05-2076
  15. Cortejoso L, Garcia MI, Garcia-Alfonso P, Gonzalez-Haba E, Escolar F, Sanjurjo M, et al. Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemotherapy and Pharmacology. 2013;71(6):1463-1472. http://doi.org/10.1007/s00280-013-2145-6
  16. Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012;118(11):2828-2836. http://doi.org/10.1002/cncr.26614
  17. Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemotherapy and Pharmacology. 2011;67(6):1323-1331. http://doi.org/10.1007/s00280-010-1425-7
  18. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology. 2010;28(20):3227-3233. http://doi.org/10.1200/jco.2009.21.7943
  19. Antonacopoulou AG, Argyriou AA, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? European Journal of Neurology. 2010;17(7):963-968. http://doi.org/10.1111/j.1468-1331.2010.02966.x
  20. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, et al. Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clinical Cancer Research. 2007;13(21):6359-6368. http://doi.org/10.1158/1078-0432.ccr-07-0660
  21. Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, et al. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. International Journal of Clinical Pharmacology and Therapeutics. 2013;51(6):475-481. http://doi.org/10.5414/CP201851
  22. Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. International Journal of Clinical Pharmacology and Therapheutics. 2010;48(11):729-734. https://doi.org/10.5414/CPP48729
  23. Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, et al. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Annals of Oncology. 2016;27(6):1143-1148. http://doi.org/10.1093/annonc/mdw074
  24. Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2009;100(7):1261-1266. http://doi.org/10.1111/j.1349-7006.2009.01186.x
  25. Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis. British Journal of Cancer. 2010;102(6):987-994. http://doi.org/10.1038/sj.bjc.6605595
  26. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. Journal of Clinical Oncology. 2009;27(33):5519-5528. http://doi.org/10.1200/jco.2008.21.6283
  27. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. British Journal of Cancer. 2008;99(7):1050-1055. http://doi.org/10.1038/sj.bjc.6604671
  28. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Journal of the National Cancer Institute. 2002;94(12):936-942. https://doi.org/10.1093/jnci/94.12.936
  29. Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, et al. Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncology Letters. 2013;6(3):648-654. http://doi.org/10.3892/ol.2013.1467
  30. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of Clinical Oncology. 2007; 25(10):1247-1254. http://doi.org/10.1200/jco.2006.08.1844
  31. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Science. 2010;101(2):530-535. http://doi.org/10.1111/j.1349-7006.2009.01418.x
  32. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of Clinical Oncology. 2010;28(15):2556-2564. http://doi.org/10.1200/jco.2009.25.2106
  33. Argyriou AA, Antonacopoulou AG, Scopa CD, Kottorou A, Kominea A, Peroukides S, et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology. 2009;77(3-4):254-256. http://doi.org/ 10.1159/000236049
  34. Lee KH, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer chemotherapy and pharmacology. 2013;71(4):843-851. http://doi.org/10.1007/s00280-013-2075-3
  35. Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, et al. Associations between glutathione S-transferase Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer epidemiology. 2010;34(2):189-193. http://doi.org/10.1016/j.canep.2010.02.008
  36. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-Oncology. 2012;14(Suppl 4):iv45-54. http://doi.org/10.1093/neuonc/nos203
  37. Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN task force report: Management of neuropathy in cancer. Journal of National Comprehensive Cancer Network. 2009;7(Suppl 5):S1-S26.
  38. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Clinical Oncology. 2006;24(14): 2158-2163. http://doi.org/10.1200/jco.2006.06.5961
  39. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research. 2005;11(16):5878-5885. http://doi.org/10.1158/1078-0432.CCR-04-2618
  40. Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, et al. Associations between UGT1A1* 6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemotherapy and Pharmacology. 2014;73(4):779-788. http://doi.org/10.1007/s00280-014-2405-0
  41. Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, et al. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced nonsmall cell lung cancer. Cancer Chemotherapy and Pharmacology. 2009;64(5):917-924. http://doi.org/10.1007/s00280-009-0943-7
  42. Di Francia R, Siesto RS, Valente D, Del Buono A, Pugliese S, Cecere S, et al. Current strategies to minimize toxicity of oxaliplatin: selection of pharmacogenomic panel tests. Anti-Cancer Drugs. 2013;24(10):1069-1078. http://doi.org/10.1097/CAD.0000000000000002
  43. Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: Chemotherapy-induced peripheral neuropathy. Methods in Molecular Biololgy Pharmacogenomics in Drug Discovery and Development. 2014;1175:301-322. http://doi.org/10.1007/978-1-4939-0956-8_12